Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.

  title={Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia.},
  author={Annamaria Colao and Antonella di Sarno and Paolo Cappabianca and Carolina Di Somma and Rosario Pivonello and Gaetano Lombardi},
  journal={The New England journal of medicine},
  volume={349 21},
BACKGROUND Whether the withdrawal of treatment in patients with nontumoral hyperprolactinemia, microprolactinomas, or macroprolactinomas is safe and effective has been unclear. We performed an observational, prospective study of cabergoline (a dopamine-receptor agonist) withdrawal in such patients. METHODS The study population included 200 patients--25 patients with nontumoral hyperprolactinemia, 105 with microprolactinomas, and 70 with macroprolactinomas. Withdrawal of cabergoline was… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 83 extracted citations

Management of macroprolactinomas

Clinical diabetes and endocrinology • 2015
View 4 Excerpts
Highly Influenced

Long-term evolution and outcomes of microprolactinoma with medical treatment.

Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion • 2013
View 7 Excerpts
Highly Influenced

Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists.

Journal of psychopharmacology • 2008
View 6 Excerpts
Highly Influenced

Cabergoline Effectively Induced Remission of Prolactinoma in a 9-year-old Japanese Boy

Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology • 2009
View 3 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 43 references

Gender differences in the prevalence , clinical features and response to cabergoline in hyperprolactinemia

A Colao, A DiSarno, P Cappabianca
Eur J Endocrinol • 2003

Long - term follow - up of pro - lactinomas : normoprolactinemia after bromocriptine withdrawal

VQ Passos, Souza JJS, Musolino NRC, Bronstein
J Clin Endocrinol Metab • 2002

Primary medical therapy of micro- and macroprolactinomas in men.

The Journal of clinical endocrinology and metabolism • 2000

The effect of quinagolide and cabergoline , two selective dopamine receptor type 2 agonists , in the treatment of prolactinomas

A DiSarno, ML Landi, P Marzullo
Clin Endocrinol ( Oxf ) • 2000

Similar Papers

Loading similar papers…